Form 4: Edwards Lifesciences Executive Equity Grants

Edwards Lifesciences Corp. reports on equity grants and option awards to Chief Financial Officer Theodora Mistras.

Summary

• Theodora Mistras, Chief Financial Officer of Edwards Lifesciences Corp. (EW), reported transactions related to equity awards on July 9, 2026.
• These transactions include the grant of restricted stock units (RSUs) and employee stock options.
• Specifically, 87,595 RSUs were granted, with vesting scheduled over three years from May 29, 2026.
• An additional 12,325 RSUs were granted, with vesting commencing one year after the grant date in four equal annual installments.
• Employee stock options for 61,800 shares were also granted with an exercise price of $91.33, vesting one year after the grant date in four equal annual installments.
• Performance rights covering a target of 12,325 shares were granted on May 7, 2026, with vesting dependent on performance goals and scheduled for July 9, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine executive compensation transactions rather than significant financial or strategic developments.

Positives

• Theodora Mistras, the CFO, has been granted significant equity awards, indicating a commitment to long-term incentive compensation.
• The grants include a mix of restricted stock units and performance rights, aligning executive compensation with company performance and long-term value creation.
• Vesting schedules are structured over multiple years, encouraging retention and sustained focus on company objectives.

Risks

• The vesting of performance rights is contingent upon achieving certain performance goals, which introduces uncertainty regarding the ultimate value of these awards.
• The exercise price of stock options ($91.33) is a significant hurdle, and the value of these options depends on future stock price performance.

Future Outlook

The future outlook for the granted equity awards depends on the achievement of performance goals for performance rights and the future stock price performance for stock options and restricted stock units. Vesting schedules indicate a multi-year commitment and potential future value realization.

Management Comments

• This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Industry Context

StockSavvy.ai notes that the issuance of equity awards to senior executives, such as the CFO, is a common practice in the medical technology industry to align executive interests with shareholder value and incentivize long-term performance.

Stakeholder Impact

• Shareholders: The grants represent potential future dilution but also an alignment of executive incentives with long-term shareholder value.
• Employees: The grants reinforce the company's compensation philosophy and may influence morale and retention among other key personnel.
• Management: The CFO's compensation is directly tied to the company's performance and stock price through these equity awards.

Next Steps

• Vesting of restricted stock units and employee stock options according to the specified schedules.
• Achievement of performance goals for the performance rights to vest.
• Potential exercise of stock options if the stock price exceeds the exercise price.

Key Dates

Keywords

Form 4, Edwards Lifesciences, EW, Theodora Mistras, CFO, Equity Grants, Restricted Stock Units, Stock Options, Performance Rights, Beneficial Ownership, SEC Filing